English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Eli Lilly And Company
Patient Daily
| May 25, 2023
Lilly ESG Report Highlights Progress Towards Sustainability Goals
Patient Daily
| May 24, 2023
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Patient Daily
| May 22, 2023
Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
Patient Daily
| May 9, 2023
Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana
Patient Daily
| May 9, 2023
Lilly Declares Second-Quarter 2023 Dividend
Patient Daily
| May 9, 2023
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
Patient Daily
| Apr 26, 2023
Lilly to Divest BAQSIMI to Amphastar
Patient Daily
| Apr 26, 2023
Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities
Trending
+
Pharmaceuticals
Patient Daily
| Jun 30, 2025
PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'
+
Pharmaceuticals
Patient Daily
| Jun 25, 2025
Neurosurgeon at the University of California: ‘340B is being exploited for profit, not patient care’
+
Pharmaceuticals
Patient Daily
| Jul 1, 2025
PhRMA chief public affairs officer on 340B drug pricing: ‘Lowering drug prices for U.S. patients starts by reining in middlemen’
1
2
3
»
Last »